Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04184297 · ClinicalTrials.gov registry record
Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to Triple Therapy
A clinical trial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 27,190
- Enrollment target
NCT04184297 is a clinical trial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 27,190 participants.
The verdict
NCT04184297 has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 27,190 participants
- Enrollment target
Study Summary
To assess the comparative effectiveness of combination Tiotropium and Olodaterol (Tio+Olo) (FDC) compared to combination LAMA/LABA and ICS (fixed or open), and to explore whether this varies across COPD sub populations defined by exacerbation risk
Interventions
- DRUG Tiotropium and Olodaterol (Tio+Olo)
- DRUG Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27,190 participants |
| Start Date | 2019-11-01 |
| Est. Completion | 2019-11-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04184297
The ClinicalTrials.gov registry entry for NCT04184297 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 27,190 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tiotropium and Olodaterol (Tio+Olo) is the first listed.
NCT04184297 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04184297 about?
NCT04184297 is a clinical study titled "Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to Triple Therapy". To assess the comparative effectiveness of combination Tiotropium and Olodaterol (Tio+Olo) (FDC) compared to combination LAMA/LABA and ICS (fixed or open), and to explore whether this varies across COPD sub populations defined by exacerbation risk
What is the current status of trial NCT04184297?
This trial is currently completed. The enrollment target is 27,190 participants. The study started on 2019-11-01. Estimated completion is 2019-11-04.
What interventions are being tested in trial NCT04184297?
The interventions under investigation include: Tiotropium and Olodaterol (Tio+Olo) (DRUG), Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS) (DRUG).
Who is sponsoring clinical trial NCT04184297?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.